Literature DB >> 7612733

Analysis of inflammatory mediators and peritoneal permeability to macromolecules shortly before the onset of overt peritonitis in patients treated with CAPD.

D Zemel1, M G Betjes, C Dinkla, D G Struijk, R T Krediet.   

Abstract

OBJECTIVE: To investigate whether changes in peritoneal membrane characteristics and inflammatory mediators in dialysate precede the onset of overt infection during continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis.
DESIGN: CAPD patients with a high peritonitis incidence stored every night bag at 4 degrees C. Routinely, each bag was thrown away after two days. Only if patients developed peritonitis, all bags were delivered for study. Thus, two night bags immediately prior to the first peritonitis bag were available for analysis. A control study was done 14 days after recovery. Dialysate samples were measured for TNF alpha, IL-6, PGE2, 6-keto-PGF1 alpha, TxB2, and serum proteins. The clearance of beta 2-microglobulin was used as an indicator of the effective peritoneal surface area. The intrinsic peritoneal permeability was characterized by the restriction coefficient.
RESULTS: Eight episodes occurred in 5 patients. The night dwells available prior to the first peritonitis effluent were drained maximally nine dwells and minimally one dwell before the first peritonitis bag. Dialysate leukocyte counts exceeded 100 x 10(6)/L only on the day of manifest infection. However, bacterial cultures were already positive at least one day before overt infection in four episodes and in three of these cases two days before. No changes were observed prior to peritonitis for the clearance of beta 2-microglobulin or the restriction coefficient. In contrast to these permeability characteristics, the cytokines, TNF alpha and, though less significant, also IL-6, were increased in dialysate one day prior to overt infection, when compared to the values obtained at the control investigation. This was especially evident in effluents drained no longer than two dwells before the first peritonitis bag. Prostaglandin concentrations in dialysate were not different before the onset of manifest peritonitis from the values measured after recovery.
CONCLUSION: In this study, the increased effective peritoneal surface area and intrinsic peritoneal permeability during acute infection appeared to be preceded by elevations in the cytokines TNF alpha and, to a lesser extent, IL-6. These increments occurred only very shortly before the onset of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612733

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  5 in total

1.  The first peritonitis episode alters the natural course of peritoneal membrane characteristics in peritoneal dialysis patients.

Authors:  Anouk T N van Diepen; Sadie van Esch; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2014-04-07       Impact factor: 1.756

Review 2.  Peritoneal dialysis. Prevention and control of infection.

Authors:  R Gokal
Journal:  Drugs Aging       Date:  2000-10       Impact factor: 3.923

Review 3.  Immune cell dysfunction and inflammation in end-stage renal disease.

Authors:  Michiel G H Betjes
Journal:  Nat Rev Nephrol       Date:  2013-03-19       Impact factor: 28.314

4.  Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.

Authors:  Johannes Thaler; Ton Lisman; Peter Quehenberger; Lena Hell; Philipp Schwabl; Bernhard Scheiner; Theresa Bucsics; Rienk Nieuwland; Cihan Ay; Michael Trauner; Ingrid Pabinger; Thomas Reiberger; Mattias Mandorfer
Journal:  Thromb Haemost       Date:  2021-07-04       Impact factor: 6.681

5.  High intraperitoneal interleukin-6 levels predict ultrafiltration (UF) insufficiency in peritoneal dialysis patients: A prospective cohort study.

Authors:  Qianhui Song; Xiaoxiao Yang; Yuanyuan Shi; Hao Yan; Zanzhe Yu; Zhenyuan Li; Jiangzi Yuan; Zhaohui Ni; Leyi Gu; Wei Fang
Journal:  Front Med (Lausanne)       Date:  2022-08-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.